Abstract

FORMULATION AND EVALUATION OF BILAYER MATRIX TABLET OF GLIBENCLAMIDE AND METFORMIN

Ravi Dasgupta*, G. Suresh Babu, T. Sri Harsha, M. Pavithra, G. Leelavathi and Grace Rathnam

ABSTRACT

The primary goal of our work is to produce a sustained release preparation with more uniform maintenance of blood plasma active concentration. Thus, potentially avoiding undesirable peaks and troughs associated with multiple immediate release preparations, and to reduce frequent dosing interval of the drug. Therefore, it is an object to produce a bilayer tablet with two different release profiles with glibenclamide as immediate release layer and metformin hydrochloride as a sustain release layer to provide a desired pharmacokinetic and therapeutic action. Rationale for combination of glibenclamide with metformin hydrochloride, suggests the use of combined formulations of medicaments capable of finding a remedy for both the deficiency in insulin secretion and the insulin resistance condition. Reduces the incidence of secondary failure of mono therapy and also increases the patient compliance by administering the drug in a single dosage form 5mg of glibenclamide and 500mg of metformin hydrochloride is suitable for the treatment of type II diabetes mellitus at any time of the progression of the disease, from its onset to most severe cases. In sudden occurrence of hyperglycemia, a dose of 5mg of glibenclamide is required to reduce the hyperglycemic effect and 500mg of metformin hydrochloride is required to sustain the normal glycemic level for the type II diabetic patient.

Keywords: Bilayer Matrix Tablet, Glibenclamide, Metformin, Diabetes mellitus.